Amarin Corp PLC News - AMRN

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Amarin Receives National Reimbursement for VAZKEPA® in Italy

-- Italian Health Authorities Approve VAZKEPA® (icosapent ethyl) for National Reimbursement to Reduce...

Amarin Appoints Peter Fishman Chief Financial Officer

DUBLIN and BRIDGEWATER, N.J., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today...

Form 8-K - Current report

Investigators to Present New REDUCE-IT Subanalysis of VASCEPA®/VAZKEPA® (icosapent ethyl) in Patients With and Without Coronary Artery Disease History and Mechanistic Data on Eicosapentaenoic Acid (EPA) at the American Heart Association’s (AHA) Annual

DUBLIN and BRIDGEWATER, N.J., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today...

Form 3 - Initial statement of beneficial ownership of securities

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Amarin Reports Third Quarter 2024 Financial Results and Provides Business Update

-- Strong Cash Position of $306 Million; 9th Consecutive Quarter of Positive or Neutral Cash Balance Total Net...

Amarin Announces Two Upcoming Investor Events

-- Company to Report Third Quarter 2024 Financial Results Wednesday, October 30 –- -- Amarin to Hold Virtual...

Research Highlighting the Clinical Impact of VASCEPA®/VAZKEPA (icosapent ethyl) in Patients with Diabetes and High Cardiovascular Risk and the Anti-Lp(a) Oxidation Mechanistic Effect of Eicosapentaenoic Acid (EPA) to be Presented at the 60th Annual Europe

DUBLIN, Ireland and BRIDGEWATER, N.J., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc...

Latest Research Highlighting VASCEPA®/VAZKEPA® (icosapent ethyl) REDUCE-IT® Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid (EPA) to be Presented at European Society of Cardiology (ESC) Congress

DUBLIN, Ireland and BRIDGEWATER, N.J., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN...

ramfan60 9 minutes ago

Yes, quite strange but with this stock, nothing surprises me.

👍️0

cloudera 9 minutes ago

If a settlement happens, Hikma will not supply IPE to the US market up to a certain date while other generics will still supply?

👍️0

ProLiberty 2 hours ago

The drop off in volume today kind of wild... after a lowish volume +9% on a bit over 1.2m shares, today the stock is -2.75% at the moment at $0.5490 (the ask) on 274k shares traded as of 2:23pm. Perhaps a jump before end of day but it stands out.

👍️0

Denisk 2 hours ago

a settlement that would specifically prohibits other vendors of generics to sell under the name "generic Vascepa" if they do not have FDA approval for CVD & do not include CVD treatment coverage in their label

👍️ 1

rosemountbomber 2 hours ago

Yes. I am not really up to speed as to what incriminating evidence Amarin had on HealthNet or how devastating it was. But as you say Hikma is imo in deep doodoo so hopefully if there is a settlement it is significantly more effective than the HN one. What I have a hard time with is what kind of settlement with Hikma would stop the other 7 or 8 Generics from stealing CVD sales.

👍️0

DAR53 3 hours ago

CaptBeer, and if so, I hope a setlement is much better than the Healthnet settlement as that did not appear to move the needle in any direction. In my opinion, Hikma is in a bad place in their infringement case.

👍️0

FlyFishingStocks 3 hours ago

poor little scorned and scorched Ralphey who wrote this less than 1 week before the long anticipated AMRN volcano exploded on the R-IT announcement.

Tuesday, September 18, 2018 3:34:10 PM
Hey hows that AMRN thing working out for you guys ....

Now he barks while drifting listless hoping his parents help with his tuitionless med schooling (since losing it chasing an AMRN falling knife)

👍️0

Whalatane 3 hours ago

Vascepa is not on the Kaiser 2025 formulary ...for anyone including Medicare part D patients
icosapent ethyl caps 1gm 2 PA; MO...is what I see

Kiwi

👍️0

Whalatane 3 hours ago

Thx for the link
Based on the most recent data available, approximately 53 million people are enrolled in Medicare Part D plans as of 20242. The total U.S. population is estimated to be around 334 million in 2024. Therefore, the percentage of the U.S. population enrolled in Medicare Part D is approximately 15.9%.
To break this down further:
53 million are enrolled in Medicare Part D plans2
This represents about 79% of the total 67 million Medicare beneficiaries2
Medicare Part D enrollees include those in stand-alone prescription drug plans and Medicare Advantage plans with drug coverage23
It's worth noting that enrollment in Medicare Part D has been steadily increasing over the years.
In 2022, about 49.8 million (77%) of the 65 million Medicare beneficiaries were enrolled in a Part D plan1.

AI generated
Kiwi

👍️0

ralphey 4 hours ago

I think they listened to this one instead .

FlyFishingStocks
May 22, 2024

I think it tests 1.70 within 3 months. That is a +91% rally before it stalls, absorbs selling, and builds a base for another leg up (possibly induced by share buyback operations?).

👍️0

CaptBeer 4 hours ago

My guess is that this case will not make it to trial but will end in a settlement in 2025.

👍️0

FlyFishingStocks 6 hours ago

FFS, How is a rumor a TA based trading strategy?
TA Strategies follow chart patterns/price action. Ever heard of the market efficiency theory? Most everything you know - or more importantly are about to know about a company - is already baked into the chart ticks.

Sleven, which TA path would you prefer ...stair step into Hell (AMRN), or be lofted suddenly into Heaven on a volcanic blast (XRP - up +523% in 65 days)?

The dogma will continue to kill you until you finally realize numbers don't lie... CEO's do.

👍 1

rosemountbomber 7 hours ago

Thanks for posting. For those who might miss it, here is the discussion concerning Amarin v Hikma:

Amarin Pharma v. Hikma Pharmaceuticals28 & Skinny LabelsHolding: The complaint plausibly pleaded induced infringement based on the label and public statements made by the generic manufacturer.The next panel from the Federal Circuit (Moore, Lourie, Albright) next dealt with what seemed like a section viii carve out ANDA case, but was rather a “run-of-the-mill induced infringement case.”29 The generic product, an icosapent ethyl already on the market, was approved for only one of the two indications (treatment of severe hypertriglyceridemia) that the NDA product (Vascepa) had been approved for, but included no limitation of use as to the second indication, and the generic manufacturer had made repeated public statements referring to itself as the “generic Vascepa,” despite being approved for only half the indications.30Unique to this case was that it was appealed from the motion to dismiss stage, and thus discovery had not occurred.31 Not in dispute however was that the complaint sufficiently alleged direct infringement, knowledge, and intent, and thus the Federal Circuit’s decision focused on whether an “inducing act” was sufficiently alleged – it was.32 Reversing the district court’s dismissal, the Federal Circuit managed to walk along the “careful balance struck by the Hatch-Waxman Act regarding section viii carve-outs,” emphasizing that this decision did not “effectively eviscerate section viii-carveouts,” as argued by Hikma, and was instead “limited to the allegations” and “guided by the standard of review appropriate for this stage of the proceedings.”33 Given those explicitly limiting statements, this decision does little to affect true section viii jurisprudence under the Hatch-Waxman Act, and thus for practitioners, reliance on cases such as GlaxoSmithKline v. Teva (2021)34 is still appropriate for skinny label analyses.

👍 3

JRoon71 7 hours ago

Kube, I think that means that for CO and VT residents, they are subject to the price disclosure noted after it (https://www.amarincorp.com/wac). Probably something to do with state-specific regulations.

Of course, that link goes to a 404, so no idea what it says.

👍 1

the_kube 8 hours ago

Looks like the discount card for $9 for 90 day supply only applies to CO and VT residents?

👍 1

DMC8 8 hours ago

https://www.womblebonddickinson.com/us/insights/articles-and-briefings/2024-hatch-waxman-year-review

👍️ 1

DMC8 8 hours ago

https://cms.amarincorp.com/sites/default/files/2025-01/Formulary_Status.pdf

👍️ 5

roadkilll 8 hours ago

HLS management is turning cash flow positive on far lower sales and growing far faster than what Amarin is able to accomplish in Europe.
Amarin has a white collar problem with a long history of rewarding the white collar club for not being profitable. Dream of what HLS management could do with Amarin. HLS is operating in Canada and a lot of what they do to get strong growth numbers would apply to Europe.
.
Craig Millian is the CEO of HLS Therapeutics and has proven he understands how to run a small pharama grow sales and turn it to profitability. Hire him and put him in as the new CEO. The Boyz we have running Amarin are getting nice pay checks and not getting the job done.

👍 1

ziploc_1 8 hours ago

The soil in the U.S. can still grow Vascepa flowers, but the U.S. soil badly needs needs fertilizer....Lr Et EPA could be that needed fertilizer.

👍 2

rosemountbomber 19 hours ago

Amarin could turn cash flow positive, IF U.S. sales of Vascepa didn't keep dropping. No generics in Canada.

👍 1

roadkilll 21 hours ago

HLS Therapeutics in Canada has the rights to Vascepa.
Q3 results - Vascepa revenue in Canada increased 30% in constant currency compared to Q3 2023 versus Q3 2024
Vascepa unit demand increased by 45% compared to Q3 2023.
The number of consistent prescribers2 for Vascepa increased 66% compared to Q3 2023.
.
This small company is about to turn cash flow positive on Vascepa related revenues/cost. Amarin????

👍 1

roadkilll 21 hours ago

Is Vazkepa looked at as a valuable drug?
We now have ((8)) generics in the US market. Yes there is a big recognition of Vasecpa making a difference in CV care.
The Europeans are a little slow in understanding a statin patient being released from the hospital after a heart attack should see Vazkepa added to their therapy. Getting to a critical number of patients and doctors in Europe will put a lot of pressure on other doctors to get on top of what is the best care for these patients. That would be hundred of thousands of HA patients that should at teast be given the choice.
.
My Doc still thinks fish oil has some medicinal value. This year he finally brought up Vascepa to me as off label use as my blood lipids edged into the treatment zone. I've actually talked to him about Vascepa in the past and he was clueless and always acted uninterested. European medicine is apparently not incentivized to keep up to date and are also on the slow track with Vazkepa. I think once that snowball of Vazkepa users gets big enough there is real potential Vaskepe it will gain traction. My Doc was actually interested in me starting Vascepa off label, for me that was a huge statement.

👍️ 9

roadkilll 21 hours ago

See the cash position. A reverse split would not get hammered in this situation.
.
A reverse split for company that is issuing stock to raise funds to keep going is what gets hammered, justly.

👍️ 1

Number sleven 22 hours ago

FFS, How is a rumor a TA based trading strategy?
Sleven,

👍️0

Jasbg 22 hours ago

MM, It is still better than the stock 'falling' !
----------------------------------

Lets see if 2025 might be where where 'the real' turnaround of Amarin 'lifesaving - prolonging' drug Vascepa - Vazkepa will finally reach the populations of Europe and China as a guaranteed safe way - for a better and longer life 🙂 ✌️

👍️ 2

mrmainstreet 23 hours ago

9% gain used to be exciting, but probably won't be again until we get back above $1 a share.

👍️ 2

DMC8 23 hours ago

Could be either same person or sitting in the same office bashing. Nothing new…

👍️ 1

Denisk 23 hours ago

Copy-cat of JR71 comments re the delisting???

seems like both of you joined this blog around the same time ????

👍️ 1

ProLiberty 24 hours ago

No. His mandate is listed equities and don't think you can find an example of this in his entire career.

👍️ 2

ramfan60 1 day ago

FFS, most of us do not suffer from indecision. We have firmly decided to see this through to the end.

👍️0

FlyFishingStocks 1 day ago

Remember this post on 11/12/24?

Trump card = Crypto.
If you were to trade your AMRN shares for XRP or BTC, you'll likely recoup your losses. Bio stocks will slump during this new administration, while crypto will perform as it paves the way to a new financial exchange system compliments of Elon Musk's influence. Rumor is he is poised to buy Ripple (XRP) which could eventually become the ledger for all derivatives trade transactions.

Just think, you could have banked a loss on your AMRN shares, bought XRP and held for 64 days, take profits (sheltered by your AMRN loss) and repurchased AMRN shares at an 8% discount.

Chart comparison: ARMN = -7.69%, XRP = +451%

TA based trading strategies are not only enormously profitable, but can also rescue a bag holder from tremendous loss.
Sadly, no one took the bait. Instead, they remain frozen in their cell of indecision, unable to act, but only hope for a miraculous turnaround yet to materialize.

👍️0

ralphey 1 day ago

You are certainly most welcome !

👍️0

DMC8 1 day ago

https://www.courtlistener.com/docket/18701895/178/amarin-pharma-inc-v-hikma-pharmaceuticals-usa-inc/

👍️0

DMC8 1 day ago

https://www.courtlistener.com/docket/18701895/178/amarin-pharma-inc-v-hikma-pharmaceuticals-usa-inc/

👍️0

rosemountbomber 2 days ago

Guess I lived another day to learn something. Apparently there has been a bill in Congress (sitting of course) to raise the annual capital loss limit from $3,000 to $14,000 and to index it to inflation. Called the Capital Loss Inflation Fairness Act. It is unfortunately being sat on by the chairman of the Ways and Means Committee.

https://stocktwits.com/GDog877/message/600060575

In case this investment never proves to be what us long term holders hope for, it might help using those losses before we all die.

👍️ 2

ramfan60 2 days ago

I hope you are correct hayward in that the Rams beat Philly. It will be a tall task...... and as far as Detroit being the last team standing, we shall see.... good luck chasing that wiry rookie Daniels all over the field. The best way to beat a Detroit offense is to have long sustained drives and keep their offense watching from the sidelines. If the Rams get another crack at them, we'll show you how it's done

👍️0

ORBAPU 2 days ago

MarketEdge today: Not sure I believe it, trying to stay hopeful.

Updated from Avoid to Neutral today.

Stock shows Mildly Improving Conditions. SCORE = 2
If you are Short this stock, hold position. Do not initiate new Short Sale.
Stock is not a Buy Candidate.

On 01/14/2025, The stock is underperforming the market over the last 50 trading days when compared to the S&P 500. The MACD-LT, an intermediate-term trend indicator, is bullish at this time. A close above $1.01 is a number to watch to confirm a trend reversal.Momentum as measured by the 14-day RSI is positive but showing signs of slowing. Over the last 50 trading sessions, there has been more volume on up days than on down days, indicating that AMRN is under accumulation, which is a bullish condition. The stock is above its 50-day moving average which is pointed down. This is supportive that the trend is improving.

👍️ 2

hayward 2 days ago

Last

All day long . The game against Detroit said it all it's all about scoring . Donaldson looked at his worst last two games . Sit back and let it fly Running out play action is in look at the good running backs swing passes make up almost half of their yardage throw in slants and quick outs then the down field dagger. KC is not going to win the Superbowl this year I think LA beats philly hurt looked bad last week IMO

👍️0

Nukemtiltheyglow 2 days ago

Ha ha, good one Hayward. Never say never....Motivation is the key. Detroit has been beaten twice this year. The Vikings were 14-3, yet got trounced by the underdog LA Rams. I don't think anyone was expecting that. The NFL is a fickle beast.
Atlanta Falcons vs New England 2017 Superbowl. Atlanta was way ahead at Half-time, yet lost the game 34-28. Stranger things have happened. New York Jets (Broadway Joe) underdogs beat the Baltimore Colts 16-7.
Some folks think the NFL is rigged? I wouldn't know?

👍️0

hayward 2 days ago

Nukemintilltheyglow

No one is going to beat Detroit its all about who is the last to score

Mike

👍️ 1

Nukemtiltheyglow 2 days ago

Behind the scenes do you think? The Rams brought in Aaron Donald to give the team a Pep talk.... 😇

👍️0

Number sleven 2 days ago

Lizzy, Thanks.
Sleven,

👍️ 1

lizzy241 2 days ago

Sleven, thanks for the link. It's a two-page document that confirms the plaintiff's submission of infringement documents.

👍 2

ramfan60 2 days ago

I think they may be able to handle this...... when they played the Jets, it was horribly cold...... they played the Niners in a monsoon rainstorm......it wasn't pretty but they won those games so they will grind it out if they have too....... if defense wins championships, I hope this defense is the real deal

👍️0

rosemountbomber 2 days ago

I hope this is the real version of who they are

I hope so too. Too many times I have seen a team look like a juggernaut one week and then, seemingly, have given their uniforms to a scout team the next week.

Hope that the colder weather in Philly doesn't affect them either.

👍️0

Number sleven 2 days ago

https://www.courtlistener.com/docket/18701895/amarin-pharma-inc-v-hikma-pharmaceuticals-usa-inc/?page=2
Sleven,

👍️0

Nukemtiltheyglow 2 days ago

Oops, sorry about that, you're correct. I don't know why I thought LA Rams were a Wildcard Team. It's the Vikings who were the Wildcard. The Team records are meaningless when it comes to playoffs. Me bad.

👍️ 1

ramfan60 2 days ago

Well Nukem, I hope a wildcard team doesn't win this year because the Rams won their division . The defense is playing dominant football but they are so young...... I hope this is the real version of who they are. They will be extra motivated to beat the Eagles so I hope they bring the same intensity to that game. As the saying goes, on any given Sunday. Mistakes are magnified. Look at the botched Baker Mayfield handoff in the Bucs/Commanders game. That cost the Bucs the game...... next weekend will be some exciting football.

👍️0

caddiedad 2 days ago

Forget 4 years ago. How about 1 year ago? We’re obviously all pot committed at this point so your hindsight attempts are utterly pointless and beyond annoying to consistent readers here. Your posts have never unearthed anything useful in this investment for me, and I’m sure many others. You have Kiwi in you and I feel that you can’t wait to eventually type “I told you so” however this all plays out. If you allegedly hold the shares you state, all this waiting and AD silence isn’t apparently forcing you to sell, and even then, there’s no verification to anything that is typed on this board anyway

👍️ 1

Meowza 2 days ago

Do you actually believe he would do something as stupid as doing a reverse split? Depends. How good does a reverse split feel in the moment?
I am in a wait mode till ...give it 9 months?

👍️0

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

Amarin Corp PLC (AMRN)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

AMRN News

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Amarin Receives National Reimbursement for VAZKEPA® in Italy

Amarin Appoints Peter Fishman Chief Financial Officer

Form 8-K - Current report

Investigators to Present New REDUCE-IT Subanalysis of VASCEPA®/VAZKEPA® (icosapent ethyl) in Patients With and Without Coronary Artery Disease History and Mechanistic Data on Eicosapentaenoic Acid (EPA) at the American Heart Association’s (AHA) Annual

Form 3 - Initial statement of beneficial ownership of securities

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Amarin Reports Third Quarter 2024 Financial Results and Provides Business Update

Amarin Announces Two Upcoming Investor Events

Research Highlighting the Clinical Impact of VASCEPA®/VAZKEPA (icosapent ethyl) in Patients with Diabetes and High Cardiovascular Risk and the Anti-Lp(a) Oxidation Mechanistic Effect of Eicosapentaenoic Acid (EPA) to be Presented at the 60th Annual Europe

Latest Research Highlighting VASCEPA®/VAZKEPA® (icosapent ethyl) REDUCE-IT® Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid (EPA) to be Presented at European Society of Cardiology (ESC) Congress

AMRN Discussion

Your Recent History

Company

Business

Popular

Get The App

Trending Now

Toplists

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

Amarin Corp PLC (AMRN) News

Amarin Corp PLC (AMRN)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

AMRN News

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Amarin Receives National Reimbursement for VAZKEPA® in Italy

Amarin Appoints Peter Fishman Chief Financial Officer

Form 8-K - Current report

Investigators to Present New REDUCE-IT Subanalysis of VASCEPA®/VAZKEPA® (icosapent ethyl) in Patients With and Without Coronary Artery Disease History and Mechanistic Data on Eicosapentaenoic Acid (EPA) at the American Heart Association’s (AHA) Annual

Form 3 - Initial statement of beneficial ownership of securities

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Amarin Reports Third Quarter 2024 Financial Results and Provides Business Update

Amarin Announces Two Upcoming Investor Events

Research Highlighting the Clinical Impact of VASCEPA®/VAZKEPA (icosapent ethyl) in Patients with Diabetes and High Cardiovascular Risk and the Anti-Lp(a) Oxidation Mechanistic Effect of Eicosapentaenoic Acid (EPA) to be Presented at the 60th Annual Europe

Latest Research Highlighting VASCEPA®/VAZKEPA® (icosapent ethyl) REDUCE-IT® Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid (EPA) to be Presented at European Society of Cardiology (ESC) Congress

AMRN Discussion

Your Recent History

Company

Business

Popular

Get The App

Go Ad-Free